US00287Y1091
© PR Newswire
15.12.2025
ABBV
LISTED
EURONEXT
AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List
News Preview
SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- AbbVie ASEAN has been ranked #15 in the inaugural Fortune Best Companies to Work For Southeast Asia 2025 list, in partnership with Great Place To Work®, highlighting workplaces across Singapore, Malaysia, Thailand and the Philippines....
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2025
ABBV
LISTED
EURONEXT
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
News Preview
Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of difficult-to-treat blood cancers NORTH CHICAGO, Ill., Dec. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data at the...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2025
ABBV
LISTED
EURONEXT
AbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Akutbehandlung von Migräne belegen
News Preview
Die entscheidende Phase-3-Studie ECLIPSE hat gezeigt, dass Atogepant Placebo hinsichtlich der Schmerzfreiheit zwei Stunden nach der Behandlung des ersten Migräneanfalls überlegen ist (24,3 % für Atogepant gegenüber 13,1 % für Placebo)1AbbVie hat bei der Europäischen Arzneimittelagentur einen Antrag auf erweiterte Zulassung von Atogepant zur akuten...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
28.11.2025
ABBV
LISTED
EURONEXT
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
News Preview
MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC)....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
25.11.2025
ABBV
LISTED
EURONEXT
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
News Preview
MONTREAL, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV), jointly with the adMare BioInnovations, announced the launch of the AbbVie Biotech Innovators Award, a prize to help foster innovation and support growth in Quebec's life sciences sector....
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2025
ABBV
LISTED
EURONEXT
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
News Preview
- EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy- In the Phase 3 EPCORE® FL-1 trial, EPKINLY + R2 demonstrated significantly superior progre...
Themefolio
Profiler
Peergroup
© PR Newswire
17.11.2025
ABBV
LISTED
EURONEXT
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer
News Preview
LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) is a hormonal medication first approved by Health Canada in 1989 for advanced prostate cancer, and later for various conditions including endometriosis, uterine fibroids, and central precocious puberty.1...
Themefolio
Profiler
Peergroup
© PR Newswire
14.11.2025
ABBV
LISTED
EURONEXT
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
News Preview
Film captures inspiring journeys of three individuals living with chronic lymphocytic leukemia (CLL)
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the United States1,2...
Themefolio
Profiler
Peergroup
© PR Newswire
13.11.2025
ABBV
LISTED
EURONEXT
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
News Preview
As a leader in migraine treatment, AbbVie is committed to addressing the impact of migraine in the workplace.
2025 honorees represent a diverse group of achievers—from teachers and authors to small business owners and aspiring yoga an...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2025
ABBV
LISTED
EURONEXT
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
News Preview
- A total of 17 abstracts, including three accepted for presentation in the Cosmetic "Top Ten" Session, underscore Allergan Aesthetics' global industry leadership across multiple aesthetic categories
- Oral abstract presentations include Phase 3 clinical study results for first-in-class botulinum neurotoxin serotype...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2025
ABBV
LISTED
EURONEXT
AbbVie Reports Third-Quarter 2025 Financial Results
News Preview
Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense ...
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2025
ABBV
LISTED
EURONEXT
The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
News Preview
Allergan Aesthetics gives patients exciting BOTOX® Cosmetic offers only in the Allē app
Buy one $50 gift card, get one free, plus, register, book a consultation, and get treated for a chance to win $25,000*†
IRVINE, Calif., Oct. 29, 2025 /PRNew...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
29.10.2025
ABBV
LISTED
EURONEXT
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
News Preview
In two replicate Phase 3 studies, upadacitinib (RINVOQ
®
) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) fr...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
ABBV
LISTED
EURONEXT
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
News Preview
Each winner will be awarded a $20,000 grant to fuel their businesses.
Since the program's inception, BOTOX® Cosmetic has awarded more than $1 million in grants to The Confidence Project entrepreneurs.
IRVINE, Calif., Oct. 21, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
20.10.2025
ABBV
LISTED
EURONEXT
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
News Preview
Upadacitinib demonstrated superiority versus adalimumab
for
primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) and ranked secondary endpoint of remission (DAS28-CRP<2.6) at week 121
SELECT-SWIT...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ABBV
LISTED
EURONEXT
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
News Preview
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).
NORTH CHICAGO, Ill., Oct....
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ABBV
LISTED
EURONEXT
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
News Preview
- Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy
NORTH CHICAGO, Ill., Oct. 13, 202...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
ABBV
LISTED
EURONEXT
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
News Preview
New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers.
NORTH CHICA...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2025
ABBV
LISTED
EURONEXT
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
News Preview
By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica®'s new packaging features a refreshed logo, modernized look, and luxe copper color palette.
The brand's new HA5® moisturizer
is designed to support...
Themefolio
Profiler
Peergroup
© PR Newswire
06.10.2025
ABBV
LISTED
EURONEXT
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
News Preview
OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total unilateral score compared to placebo.1...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ABBV
LISTED
EURONEXT
AbbVie to Host Third-Quarter 2025 Earnings Conference Call
News Preview
NORTH CHICAGO, Ill., Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2025
ABBV
LISTED
EURONEXT
Natrelle® Awarded Supplier Agreement from Vizient
News Preview
This agreement grants Vizient clients enhanced access to Natrelle®, the broadest selection of breast implant options on the market.
IRVINE, Calif., Oct. 1, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that Natrelle® has been named a supplier by Vizient,...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ABBV
LISTED
EURONEXT
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
News Preview
Expansion increases biologics manufacturing for immunology and oncology medicines
Milestone marks progress on
AbbVie's long-term commitment to U.S. manufacturing...
Themefolio
Profiler
Peergroup
© PR Newswire
29.09.2025
ABBV
LISTED
EURONEXT
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
News Preview
New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines
Facility expected to be fully operational and serving patients by 2027...
Themefolio
Profiler
Peergroup
© PR Newswire
29.09.2025
ABBV
LISTED
EURONEXT
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
News Preview
The list price will be consistent with the United States to reflect the value of the innovation
AbbVie is committed to ensuring that developed nations fully recognize the value of our medicines in improving patient outcomes, consistent...
Themefolio
Profiler
Peergroup
© PR Newswire
26.09.2025
ABBV
LISTED
EURONEXT
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
News Preview
Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrumPositive results across all three Phase 3 TEMPO trials reinforce the potential of tavapadon, a novel selective dopamine D1/D5 receptor partial agonist, in Parkinson's diseaseIf approved, tavapadon will enhan...
Themefolio
Profiler
Peergroup
© PR Newswire
25.09.2025
ABBV
LISTED
EURONEXT
QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published
News Preview
- Expanded access provides an additional treatment option for those with chronic migraine.- AbbVie is dedicated to people living with this debilitating disease and continues its commitment by providing multiple treatments and programs for these individuals.
MONTREAL, Sept. 25, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today tha...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
ABBV
LISTED
EURONEXT
AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta
News Preview
VRAYLAR® is an atypical antipsychotic medication with partial agonist activity at central dopamine D3 receptors in addition to targeted activity at D2 and serotonin 5-HT1A and 5-HT2A receptors.1MONTREAL, Sept. 15, 2025 /CNW/ - AbbVie (NYSE: ABBV) announced today that Alberta has listed VRAYLAR® (cariprazine) on its Health Drug Formulary.2
This li...
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2025
ABBV
LISTED
EURONEXT
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
News Preview
Building on the brand's 20-year legacy and real-world experience, the original BOTOX® Cosmetic continues to be the most researched and requested product of its kind.1,2BOTOX® Cosmetic is trusted by aesthetic providers with 95% of specialists choosing it for themselves, their friends, and family.3This campaign is BOTOX® Cosmetic's largest ever, ap...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
ABBV
LISTED
EURONEXT
AbbVie Declares Quarterly Dividend
News Preview
NORTH CHICAGO, Ill., Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
The cash dividend is payable November 14, 2025, to stockholders of record at the close of business on October 15, 2025.
Since the company's inception in 2013, AbbVie has increased its dividend by 31...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2025
ABBV
LISTED
EURONEXT
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
News Preview
Data presented at 13th Society of Hematologic Oncology (SOHO) Annual MeetingNORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and monitoring patients in the outpatient setting for the first full dose of epco...
Themefolio
Profiler
Peergroup
© PR Newswire
03.09.2025
ABBV
LISTED
EURONEXT
Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers
News Preview
First-of-its-kind report is available at www.naturallyyouwithHA.com Deep dive into category education and data on HA injectable fillers and the natural-looking results they can achieveIRVINE, Calif., Sept. 3, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, has launched the "Naturally You with Injectable Hyaluronic Acid Fillers" campa...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ABBV
LISTED
EURONEXT
Health Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers
News Preview
Health Canada has approved ELAHERE®, the first novel therapy to demonstrate statistically significant and clinically meaningful improvements in overall survival (OS) compared to chemotherapy alone for patients with platinum-resistant ovarian cancer (PROC).1ELAHERE® received approval through Health Canada's Priority Review process, based on data f...
Themefolio
Profiler
Peergroup
© PR Newswire
02.09.2025
ABBV
LISTED
EURONEXT
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
NORTH CHICAGO, Ill., Sept. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025. Management will participate in a fireside chat at 9:00 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relati...
Themefolio
Profiler
Peergroup
© PR Newswire
01.09.2025
ABBV
LISTED
EURONEXT
AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work
News Preview
SINGAPORE, Sept. 1, 2025 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture, has selected AbbVie for the 2025 Best Workplaces in Asia™ List, ranking the company No. 7 up from No. 8 last year.
This year'...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2025
ABBV
LISTED
EURONEXT
RINVOQ® (upadacitinib) Receives Health Canada Notice of Compliance (NOC) for Giant Cell Arteritis in adults
News Preview
RINVOQ is the first and only oral advanced therapy approved for the treatment of giant cell arteritis (GCA) in Canadian adults1GCA is the most common vasculitis in Canada, primarily affecting adults over 502This marks the eighth approved indication for RINVOQ in Canada across rheumatology, gastroenterology and dermatology3MONTREAL, Aug. 27, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ABBV
LISTED
EURONEXT
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
News Preview
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).Bretisilocin is a novel, short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser.NORTH CHICAGO, Ill. and NEW YORK, Aug. 25, 2025 /PRNewswire/ -- AbbVie (...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2025
ABBV
LISTED
EURONEXT
AbbVie Completes Acquisition of Capstan Therapeutics
News Preview
Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivoNORTH CHICAGO, Ill., Aug. 19, 2025 /PRNewswire/ --...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2025
ABBV
LISTED
EURONEXT
SkinMedica® Unveils Its Newest Hydration Hero
News Preview
By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica® introduces a next generation amino acid–based cleanser: HA5® Hydra Collagen Hydrating Foaming Cleanser.IRVINE, Calif, Aug. 19, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today the newest addition to the SkinMedica® HA5® Hydra Collagen portf...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2025
ABBV
LISTED
EURONEXT
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
News Preview
New $195 million facility will further enhance AbbVie's active pharmaceutical ingredient (API) production capacity and capabilities in the U.S.Expansion is part of AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decadeConstruction will begin in fall 2025 with the site expected to be fu...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
ABBV
LISTED
EURONEXT
AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia
News Preview
VRAYLAR, an atypical antipsychotic medication, received its Notice of Compliance from Health Canada on April 22, 2022.Following the positive recommendation from INESSS issued in October 2022, VRAYLAR completed negotiations at pCPA and has an active letter of intent (LOI). Québec and the federal plans (NIHB, CSC and VAC) have subsequently listed V...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
ABBV
LISTED
EURONEXT
AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
News Preview
More than 400 undergraduate and graduate students in the U.S. have benefited from the AbbVie Immunology Scholarship since its inception in 2016NORTH CHICAGO, Ill., Aug. 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the 2024-2025 recipients of the AbbVie Immunology Scholarship, aimed to support students living with chronic, inflamma...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
ABBV
LISTED
EURONEXT
SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
News Preview
SkinMedica®, by the makers of BOTOX® Cosmetic (onabotulinumtoxinA) launches the first and only product to use a proprietary complex of five forms of Hyaluronic Acid (HA) and Hydra Collagen, plus Advanced VITISENSCE® Technology for deeper hydrationIRVINE, Calif., Aug. 27, 2024 /PRNewswire/ -- For 25 years, SkinMedica® has been at the forefront of...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2024
ABBV
LISTED
EURONEXT
European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
News Preview
TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyFL is an incurable form of non-Hodgkin's lymphoma (NH...
Themefolio
Profiler
Peergroup
© PR Newswire
15.08.2024
ABBV
LISTED
EURONEXT
AbbVie Announces Ontario and Quebec are First Provinces to Reimburse Subcutaneous EPKINLY™ (epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process
News Preview
MONTREAL, Aug. 15, 2024 /CNW/ - AbbVie (NYSE: ABBV), today announced that EPKINLY is now listed on the Ontario Health (Cancer Care Ontario) formulary under the NDFP (New Drug Funding Program) and the HCTFP (High Cost Therapy Funding Program) programs1 and the Régie de l'assurance maladie du Québec (RAMQ) Liste des médicaments - Établissements2 fo...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
